Table 2 Univariable analysis of development of NFV resistance at failure
Variable | Odds ratio | 95% CI | p Value |
|---|---|---|---|
log | 1.40 | 0.64 - 3.04 | .39 |
| 0.65 | 0.45 - 0.94 | .02 |
| 0.98 | 0.97 - 0.99 | .01 |
GSS Other , per unit higher | 0.53 | 0.39 - 0.71 | < .001 |
ΔT, per month more | 1.00 | 0.99 - 1.01 | .74 |
Sub, as B | 1.63 | 0.83 - 3.22 | .16 |
, per unit higher
, per additional mutation
, per 10 generations more- Univariable association of factors at baseline with risk of nelfinavir (NFV) resistance development at treatment failure: fitness under NFV treatment (log
), expected number of mutations to NFV resistance (
), expected number of generations to NFV resistance (
), time between baseline and follow-up sequence (ΔT), the activity of the other drugs in the combination (GSS
Other
) and the subtype distribution (Sub).